Navidea Biopharmaceuticals, Inc. (NAVB)

NAVB Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2022	2021	2020	2019	2018
Market Capitalization	0	6	29	51	18	18
Market Cap Growth	14.63%	-79.00%	-42.89%	183.29%	3.59%	-69.78%
Enterprise Value	-3	7	26	50	18	14
PE Ratio	-	-0.36	-2.50	-4.83	-1.66	-1.09
PS Ratio	82.04	93.86	55.21	56.15	681.33	54.28
PB Ratio	-2.72	-0.73	-275.38	39.05	-11.25	10.12
P/FCF Ratio	-0.90	-0.66	-2.78	-5.98	-1.93	4.14
P/OCF Ratio	-0.92	-0.69	-2.87	-6.29	-1.94	4.09
EV/Sales Ratio	10340.83	100.54	48.66	54.69	682.14	44.48
EV/EBITDA Ratio	-0.67	-0.47	-2.08	-4.67	-1.66	-2.58
EV/EBIT Ratio	-0.66	-0.47	-2.07	-4.64	-1.63	-2.51
EV/FCF Ratio	-0.64	-0.70	-2.45	-5.83	-1.93	3.39
Debt / Equity Ratio	-0.38	-0.29	-7.03	1.02	-0.66	0.45
Debt / EBITDA Ratio	-0.13	-0.17	-0.06	-0.12	-0.10	-0.06
Debt / FCF Ratio	-0.13	-0.26	-0.07	-0.16	-0.11	0.07
Quick Ratio	0.49	0.20	0.82	1.20	0.51	1.27
Current Ratio	0.56	0.32	1.02	1.38	0.76	1.47
Asset Turnover	0.00	0.02	0.08	0.12	0.01	0.05
Interest Coverage	20.79	-12.79	-1895.99	0	-433.51	-352.20
Return on Equity (ROE)	77.54%	204.07%	11009.17%	-808.75%	678.88%	-932.36%
Return on Assets (ROA)	-44.53%	-393.79%	-176.54%	-137.15%	-263.69%	-230.08%
Return on Capital (ROIC)	505.74%	234.12%	-1876.01%	-403.89%	2017.25%	-530.25%
Earnings Yield	-5070.78%	-279.37%	-39.98%	-20.71%	-60.35%	-92.12%
FCF Yield	-19797.48%	-152.17%	-35.95%	-16.72%	-51.89%	24.16%
Buyback Yield / Dilution	-223.32%	-	-22.80%	-66.02%	-68.80%	-2.72%
Total Shareholder Return	-223.32%	-	-22.80%	-66.02%	-68.80%	-2.72%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.